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Introduction. Patients with head and neck cancer suffer from various impairments due to the primary illness, as well as secondary
consequences of the oncological treatment. This systematic review describes the effects of radiotherapy and/or chemotherapy on
the functions of the upper aerodigestive tract in patients with head and neck cancer. Methods. A systematic literature search was
performed by two independent reviewers using the electronic databases PubMed and Embase. All dates up to May 2016 were
included. Results. Of the 947 abstracts, sixty articles met the inclusion criteria and described one or more aspects of the sequelae
of radiotherapy and/or chemotherapy. Forty studies described swallowing-related problems, 24 described voice-related problems,
seven described trismus, and 25 studies described general quality of life.Only 14 articles reported that speech pathologists conducted
the interventions, of which only six articles described in detail what the interventions involved. Conclusion. In general, voice
quality improved following intervention, whereas quality of life, dysphagia, and oral intake deteriorated during and after treatment.
However, as a consequence of the diversity in treatment protocols and patient characteristics, the conclusions ofmost studies cannot
be easily generalised. Further research on the effects of oncological interventions on the upper aerodigestive tract is needed.
1. Introduction
Head and neck oncological patients suffer from various
functional, physical, and emotional impairments due to both
the primary illness and the secondary consequences of the
tumor treatment [1]. The oncological treatment of head and
neck tumors depends on the location and the stage of the
tumor, as well as the treatment preferences of the individual
patient. Head and neck oncological treatment can include
surgery, radiotherapy, chemotherapy, or combinations of
these. The impact of head and neck oncological treatments
on the anatomical structures, organ function, and the quality
of life (QoL) should not be underestimated [2]. For instance,
the implications of loss of function for people treated nonsur-
gically for head and neck cancer (HNC) and its detrimental
effects on functioning and QoL are well documented [3].
In order to assist people with dysphagia to adjust to and
live successfully with the sequelae of the primary condition,
speech pathologists managing this caseload need to ensure
posttreatment services are available [4] that address not only
the physical but also the emotional and psychosocial needs.
A qualitative study by Nund et al. [5] exploring dysphagia
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management by speech pathologists suggests that care givers
generally feel ill-prepared for their role. Furthermore, this
study suggests that clinicians should provide adequate and
timely training and support to carers. Furthermore, Krisciu-
nas et al. [6] concluded that within speech pathology there is
no standardised therapy forHNCpatients and scant evidence
to support any particular protocol. As a result, institutions
and individual speech pathologists need to develop their
own protocols based on “standard” practices or anecdotal
evidence.
Evidence-based practice (EBP) is hailed to be paramount
in the practice of speech pathology [7]. The Ameri-
can Speech-Language-Hearing Association (ASHA) defines
evidence-based practice as “. . .an approach in which current,
high-quality research evidence is integrated with practitioner
expertise and client preferences and values, into the process
of making clinical decisions” [8]. Essentially, EBP involves
moving the foundation for clinical decisions from clinical
protocols centered solely on expert opinion to the integration
of clinical expertise, the best current research evidence,
and individual client values. To facilitate EBP in healthcare,
clinical practice guidelines can be developed to summarise
clinically relevant evidence [9].
Several reviews have been published about the outcomes
after radiotherapy and/or chemotherapy in HNC patients
(e.g., Frowen and Perry [10]; Jacobi et al. [11]; van der Molen
et al. [12]; Paleri et al. [13]; Roe et al. [14]). Most of the reviews
focused on selected functional domains in populations with
HNC: health-related QoL [15], swallowing [13, 14, 16], and
voice and speech [11]. Only the review by van der Molen et al.
[12] covered a wider range of functional outcomes in patients
with advanced HNC, including swallowing, mouth opening,
nutrition, pain, and QoL. Further, the purpose of some
studies was to provide evidence-based clinical guidelines
(e.g., Paleri et al. [13]) and they did not perform systematic
literature searches in linewith the PRISMAguidelines [17]. As
such, even though a number of reviews have been published
over the last ten years, a comprehensive updated systematic
review is needed that includes all functional domains affected
by radiotherapy and/or chemotherapy in patients with head
and neck carcinoma.
A systematic review was conducted to describe the effects
of radiotherapy and/or chemotherapy on functions of the
upper aerodigestive tract in patients withHNCand examined
the evidence of interventions by speech pathologists.
2. Methods
Asystematic literature searchwas performed by two indepen-
dent reviewers.The electronic biomedical databases PubMed
and Embase were used (search period from start of database
until 5 May 2016). The searches were limited to English
language publications. In PubMed the MeSH terms larynx
or hypopharynx were combined with all MeSH terms related
to head and neck neoplasms (Table 1). Next, the results were
linked to all MeSH terms for chemotherapy or radiotherapy,
after which the outcome was combined with all MeSH
terms found for dysfunctions of the upper aerodigestive tract
and limited with adults +19 years. The exact syntax of the
literature search is presented in Table 1.
In Embase the thesaurus terms larynx or hypopharynx
were linked to neoplasm and radiotherapy or chemotherapy.
Next, the search outcome was combined with the following
terms: dysphagia, speech, speech disorder, voice, dysphonia,
xerostomia, quality of life, dysarthria, or trismus (see Table 1).
To identify the most recent publications, the search
was complemented by free text words in PubMed and
Embase (for the period after April 2015 until May 2016).
Truncation symbols and wildcards were used to search for
variant forms of words or word extensions: Laryn∗, pharyn∗
or hypopharyn∗ were combined with cancer∗, neoplasm∗,
tumour∗ or carcinoma∗. Furthermore, these free text words
were combined with radiation∗, radiotherap∗, chemotherap∗,
adjuvant therap∗ or radiochemotherap∗ and, finally, com-
bined with deglut∗, swallow∗, dysphag∗, speech∗, voic∗, artic-
ulat∗, dysphon∗, quality of life∗, xerostom∗, dysarthr∗ or
anarthr∗.
Only articles presenting both pre- and postintervention
data of the upper aerodigestive tract functions of the partici-
pants were included. Review articles and studies with a popu-
lation sample of less than 20 patients were excluded, as well as
experiments on animals or articles not published in English.
Furthermore, studies published before 1990, case reports,
expert opinions, and articles describing combinations of
therapy including surgical interventions were excluded.
Final decisions on inclusion were made based on the
original articles by consensus between two expert reviewers
in accordance with the PRISMA statement [17].The reference
lists of all the included articles were searched for additional
literature. Next, the standard quality assessment QualSyst
as described by Kmet et al. [18] was performed in order
to evaluate the methodological strength and weaknesses of
the included studies. All ratings were performed by two
independent reviewers. After consensus, studies with poor
methodology scores (<50%) were excluded. All included
articles were classified according to the Australian National
Health and Medical Research Council (NHMRC) Evidence
Hierarchy [19]. Data were retrieved from all studies and
tabulated; further details on selected speech pathology inter-
ventions were summarised separately.
3. Results
Using MeSH or thesaurus terms, 304 articles were located in
PubMed and 201 in Embase. Free text word searches resulted
in another 148 articles in PubMed and 397 in Embase. The
combination of these searches, without overlap, yielded 947
articles. Figure 1 outlines the PRISMA reviewing process
according to Moher et al. [20]. Sixty articles met all inclusion
criteria.
Table 2 shows the outcomes of the QualSyst critical
appraisal tool by Kmet et al. [18]. As all studies had sufficient
methodological quality, no further studies were excluded; the
overall methodological quality ranged from adequate to good
with 0 studies ranked as poor, 3 studies as adequate, 3 studies
as good, and 54 studies as strong. Based on the NHMRC
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Table 1: Search strategies per literature database.
Database and search terms Limits Number ofrecords
Subject headings
Embase: (larynx/OR pharynx/OR hypopharynx/) AND (neoplasm/OR larynx
disorder/OR pharynx disorder/OR larynx cancer/OR larynx carcinoma/OR
pharynx cancer/OR pharynx carcinoma/)
AND (radiotherapy/OR chemotherapy/OR chemoradiotherapy/OR adjuvant
therapy/OR drug therapy/)
AND (speech sound disorder OR speech/or speech disorder/OR swallowing/OR
dysphagia/OR dysphonia/OR voice disorder/OR aphonia/OR speech
intelligibility/OR xerostomia/OR dysarthria/OR esophagus speech/OR larynx
prosthesis/OR trismus/OR “quality of life”/)
English 201
Subject headings
PubMed: (“Larynx”[Mesh] OR “Pharynx”[Mesh] OR “Hypopharynx”[Mesh]) AND
(“Neoplasms”[Mesh] OR “Head and Neck Neoplasms”[Mesh] OR “Neoplasms,
Second Primary”[Mesh] OR “Pharyngeal Neoplasms”[Mesh] OR “Oropharyngeal
Neoplasms”[Mesh] OR “Tonsillar Neoplasms”[Mesh] OR “Nasopharyngeal
Neoplasms”[Mesh] OR “Mouth Neoplasms”[Mesh] OR “Laryngeal
Neoplasms”[Mesh] OR “Tongue Neoplasms”[Mesh] OR “Thyroid
Neoplasms”[Mesh] OR “Salivary Gland Neoplasms”[Mesh] OR “Jaw
Neoplasms”[Mesh] OR “Lip Neoplasms”[Mesh] OR “Thyroid Carcinoma,
Anaplastic”[Mesh] OR “Neoplasms, Squamous Cell”[Mesh] OR “Neoplasms, Basal
Cell”[Mesh] OR “Otorhinolaryngologic Neoplasms”[Mesh] OR “Hypopharyngeal
Neoplasms”[Mesh] OR “Laryngeal Diseases”[Mesh] OR “Pharyngeal
Diseases”[Mesh]) AND (“Radiotherapy”[Mesh] OR “Radiotherapy,
Adjuvant”[Mesh] OR “Radiotherapy, High-Energy”[Mesh] OR “Radiotherapy,
Image-Guided”[Mesh] OR “Radiotherapy, Intensity-Modulated”[Mesh] OR
“Radiotherapy, Conformal”[Mesh] OR “Radiotherapy, Computer-Assisted”[Mesh]
OR “Radiotherapy Planning, Computer-Assisted”[Mesh] OR “Radiotherapy
Dosage”[Mesh] OR “Brachytherapy”[Mesh] OR “Radiosurgery”[Mesh] OR
“Radiation Oncology”[Mesh] OR “Dose-Response Relationship, Radiation”[Mesh]
OR “Consolidation Chemotherapy”[Mesh] OR “Induction Chemotherapy”[Mesh]
OR “Maintenance Chemotherapy”[Mesh] OR “Chemotherapy, Adjuvant”[Mesh]
OR “Chemotherapy, Cancer, Regional Perfusion”[Mesh] OR “Drug
Therapy”[Mesh] OR “DrugTherapy, Combination”[Mesh] OR
“Radiotherapy”[Mesh] OR “Radiation Dosage”[Mesh]) AND (“Articulation
Disorders”[Mesh] OR “Speech”[Mesh] OR “Speech Sound Disorder”[Mesh] OR
“Speech, Esophageal”[Mesh] OR “Speech, Alaryngeal”[Mesh] OR “Speech
Intelligibility”[Mesh] OR “Speech Disorders”[Mesh] OR “Deglutition
Disorders”[Mesh] OR “Deglutition”[Mesh] OR “Dysphonia” [Mesh] or “Voice
Disorders” [Mesh] or “Hoarseness” [Mesh] or “Aphonia” [Mesh] OR
“Xerostomia”[Mesh] OR “Dysarthria”[Mesh] OR “Larynx, Artificial”[Mesh] OR
“Speech, Esophageal”[Mesh] OR “Trismus”[Mesh] OR “Quality of Life”[Mesh])
Adult: 19+ years
English 304
Free text
Embase: (larynx∗ or pharynx∗ OR hypopharyn∗ OR laryngo∗ OR larynge∗) AND
(cancer OR cancers OR neoplasm∗ OR tumour∗ OR tumor OR tumors OR
carcinoma∗) AND (radiation∗ OR radiotherap∗ OR chemotherap∗ OR adjuvant
therap∗ OR radiochemotherap∗) AND (deglut∗ OR swallow∗ OR dysphag∗ OR
speech∗ OR voic∗ OR hoarse∗ OR aphon∗ OR rough∗ OR articulat∗ OR dysphon∗
OR (quality AND life) OR xerostom∗ OR dysarthr∗ OR anarthr∗ OR trismus)
Publication date:
last year 397
Free text PubMed: As per Embase Free Text
Publication date:
from 2015/05/05 to
2016/05/05
148
Evidence Hierarchy [19], 6 studies were classified as level II
evidence and 54 studies as level III evidence.
All 60 studies focused on different functions of the upper
aerodigestive tract following radiotherapy and/or chemother-
apy for HNC.The following constructs were evaluated across
the different studies: communication (voice and speech),
functions of the digestive tract (oral intake, weight loss,
dysphagia, trismus, xerostomia, and tube dependency), QoL,
and overall survival rates.
Table 3 provides a summary of the 60 retrieved observa-
tional and intervention studies thatmet the inclusion criteria.
The first column presents the reference of the author(s).
The second column represents the number of subjects, the
third column represents the etiology of the head and neck
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947
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Records excluded based on 
inclusion/exclusion criteria: 815 
(i) Not about effects of radiotherapy
and/or chemotherapy on upper 
aerodigestive tract in HNC patients
(ii) No pre- and postintervention data
(iv) Publication date before 1990
(v) Article not in English
(vi) Case report, expert opinion, 
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Full-text articles excluded based on 
inclusion/exclusion criteria: 85
Articles included through reference list
check: 13
Total number of articles included:
60
Duplicates removed: 103
(iii) Population sample <20 patients
Figure 1: PRISMA flowchart.
malignancies, and the 4th column displays the staging of the
malignancies. The 5th column shows whether voice and/or
speech, digestive tract, andQoLwere studied.The 6th and 7th
columns show the evaluation techniques and the treatment,
respectively. The 8th column presents the follow-up and the
last column describes the author’s key findings.
3.1. Voice and/or Speech Function. Twenty-four studies eval-
uated voice and/or speech function [21–43] with a follow-
up time ranging from 1-month follow-up [42] to ten-year
follow-up [43]. Most studies included patients with laryngeal
tumors only; however 11 studies [22, 27, 29, 30, 33–37, 44] also
included nonlaryngeal tumors. Seventeen studies [21, 23, 25,
26, 28, 30–32, 34–36, 38–43] included patientswith low-grade
tumors (i.e., T1 and T2) and 15 studies included patient with
advanced tumors [22, 24, 27, 29–37, 40, 42, 44].
Nine studies [23, 28, 30, 32, 33, 35, 38, 42, 44] used
acoustic analysis to evaluate voice quality, six studies [24–
26, 34, 35, 39] used the Voice Handicap Index, and three
studies [21, 38, 43] used videolaryngostroboscopy. In several
studies, either descriptions of how voice quality was evaluated
were missing or nonvalidated tools were used (e.g., patients
self-reporting or trial-specific questionnaires). Only four
studies [23, 31, 40, 44] reported whether the patient received
any voice therapy.
All the studies reported good to excellent outcomes for
voice quality at long-term follow-up. Some studies specifi-
cally reported pre- to posttreatment improvements of voice or
speech quality following radiotherapy and/or chemotherapy
[22, 23, 28]. However, other studies [36, 40, 42, 44] reported
a deterioration after therapy at long-term follow-up. Al-
Mamgani et al. [26] found a better voice outcome in case
of single vocal cord irradiation compared with irradiation of
the whole larynx. Mittal et al. [37] concluded that radiation
with tissue/dose compensation (TDC) improved articulatory
outcome compared to radiation without TDC.
3.2. Functions of the Digestive Tract. Forty studies [16, 22, 29,
34–37, 42, 45–76] describe the effects of radiotherapy and/or
chemotherapy on the functions of the digestive tract and used
BioMed Research International 5
Table 2: Methodological quality based on QualSyst critical appraisal tool by Kmet et al. 2004 [18] and NHMRC 1999 [19] evidence level of
included articles.
Reference Kmet score (%) Methodological quality1 NHMRC level of evidence2
Aaltonen et al. 2014 [21] 25/28 (89%) Strong II
Ackerstaff et al. 2009 [22] 22/28 (79%) Good II
Agarwal et al. 2009 [23] 19/24 (79%) Good III-2
Agarwal et al. 2011 [45] 17/20 (85%) Strong III-3
Akst et al. 2004 [46] 17/20 (85%) Strong III-3
Al-Mamgani et al. 2012 [24] 19/20 (95%) Strong III-3
Al-Mamgani et al. 2012 [47] 21/22 (95%) Strong III-3
Al-Mamgani et al. 2013 [25] 21/22 (95%) Strong III-3
Al-Mamgani et al. 2015 [26] 21/22 (95%) Strong III-3
Bansal et al. 2004 [27] 14/24 (58%) Adequate III-3
Bibby et al. 2008 [28] 18/22 (82%) Strong III-2
Bottomley et al. 2014 [78] 24/28 (86%) Strong II
Buchbinder et al. 1993 [48] 14/26 (54%) Adequate III-1
Caudell et al. 2010 [49] 21/22 (95%) Strong III-3
Christianen et al. 2015 [50] 21/22 (95%) Strong III-3
Cohen et al. 2006 [51] 19/20 (95%) Strong III-3
Dornfeld et al. 2007 [29] 17/22 (77%) Strong III-3
Dijkstra et al. 2007 [52] 19/22 (86%) Strong III-3
Feng et al. 2007 [53] 19/22 (86%) Strong III-3
Feng et al. 2010 [54] 20/20 (100%) Strong III-3
Frowen et al. 2010 [16] 22/22 (100%) Strong III-2
Haderlein et al. 2014 [55] 17/20 (85%) Strong III-3
Hutcheson et al. 2014 [56] 18/20 (90%) Strong III-3
Jacobi et al. 2016 [30] 17/18 (94%) Strong III-3
Karlsson et al. 2015 [31] 26/28 (93%) Strong II
Karlsson et al. 2016 [32] 18/20 (90%) Strong III-3
Kazi et al. 2008 [33] 17/20 (85%) Strong III-2
Kerr et al. 2015 [34] 19/20 (95%) Strong III-2
Kotz et al. 2012 [57] 24/28 (86%) Strong II
Kraaijenga et al. 2014 [35] 19/20 (95%) Strong III-3
Kumar et al. 2014 [58] 19/20 (95%) Strong III-2
Lazarus et al. 2014 [36] 19/20 (95%) Strong III-3
List et al. 1999 [59] 15/18 (83%) Strong III-3
McLaughlin et al. 2010 [60] 19/20 (95%) Strong III-3
Mittal et al. 2001 [37] 16/20 (80%) Strong III-3
Murry et al. 1998 [61] 11/20 (55%) Adequate III-3
Niedzielska et al. 2010 [38] 17/20 (85%) Strong III-2
Nourissat et al. 2010 [62] 23/26 (88%) Strong III-3
Ottoson et al. 2014 [63] 19/22 (86%) Strong III-3
Pauli et al. 2013 [64] 19/22 (86%) Strong III-3
Pauloski et al. 2006 [65] 18/20 (90%) Strong III-3
Rademaker et al. 2003 [66] 17/20 (85%) Strong III-3
Remmelts et al. 2013 [39] 18/20 (90%) Strong III-3
Salama et al. 2008 [67] 17/20 (85%) Strong III-3
Sanguineti et al. 2014 [40] 19/20 (95%) Strong III-3
Scrimger et al. 2007 [68] 18/20 (90%) Strong III-3
Spector et al. 1999 [41] 17/22 (77%) Good III-3
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Table 2: Continued.
Reference Kmet score (%) Methodological quality1 NHMRC level of evidence2
Starmer et al. 2014 [69] 18/20 (90%) Strong III-3
Stenson et al. 2010 [70] 16/20 (80%) Strong III-3
Strigari et al. 2010 [71] 17/20 (85%) Strong III-3
Tuomi et al. 2015 [42] 18/20 (90%) Strong III-2
Urdaniz et al. 2005 [77] 18/20 (90%) Strong III-2
Vainshtein et al. 2015 [72] 20/24 (83%) Strong III-3
van der Molen et al. 2011 [73] 24/26 (92%) Strong II
van der Molen et al. 2012 [44] 16/20 (80%) Strong III-3
van der Molen et al. 2013 [74] 19/20 (95%) Strong III-3
Verdonck-de Leeuw et al. 1999 [43] 18/20 (90%) Strong III-2
Verdonck-de Leeuw et al. 2014 [79] 16/20 (80%) Strong III-2
Vlacich et al. 2014 [75] 18/20 (90%) Strong III-3
Wilson et al. 2011 [76] 18/20 (90%) Strong III-3
1Methodological quality: strong > 80%; good 60–79%; adequate 50–59%; poor < 50%.
2NHMRC evidence hierarchy designates the following hierarchy: level I (evidence obtained from a systematic review of all relevant RCTs), level II (evidence
obtained from at least one properly designed RCT), level III-1 (evidence obtained from well-designed pseudo-RCTs [alternate allocation or some other
method]), level III-2 (evidence obtained from comparative studies with concurrent controls and allocation not randomised [cohort studies], case control
studies, or interrupted time series with a control group), level III-3 (evidence obtained from comparative studies with historical control, two ormore single-arm
studies, or interrupted time series without a parallel control group), and level IV (evidence obtained from case series, either posttest or pretest and posttest).
a variety of outcomemeasures. Of these 40 studies, 16 studies
[16, 35, 37, 45, 49, 53, 54, 56, 58, 63, 65, 67, 69, 70, 73, 74]
used videofluoroscopy to measure physiological changes in
swallowing function. Eight studies [29, 35, 46, 47, 49, 55,
60, 75] used feeding tube dependency as a (dichotomous)
outcome, whereas seven studies [35, 46, 57, 65, 66, 69, 73]
described the level of oral intake in more detail. Only four
studies [35, 36, 56, 76] used a condition specific validated
measure for swallowing disorders (e.g., MDADI).
With regard to nutritional status, five studies [29, 60, 62,
63, 73] used the body mass index as an outcome or reported
specifically on weight gain or loss. Seven studies [35, 36, 48,
52, 64, 73, 74] used the presence of trismus as an outcome by
reporting on themaximumdistance ofmouth opening. Saliva
flow (as a measure of xerostomia) was used in four studies
[36, 37, 68, 71].
Follow-up times in these studies range from immediately
after therapy [62] to 6 years after therapy [35], describing
both low stage tumors and more advanced tumors. Thirty-
two studies used the TNM-classification system, stage was
described in six other studies, and the remaining two studies
did not report on tumor stage or grade. However, it was
unclear whether the clinical TNM-score or the pathological
TNM-score was used to describe the severity of the disease.
Eight studies [16, 35, 46, 48, 52, 56, 57, 69, 73, 74] described
whether the patients received functional treatment (by a
speech pathologist); the remainder of the articles did not
mention whether the patient received any additional treat-
ment.
Nine studies reported impaired swallowing function fol-
lowing radiotherapy and/or chemotherapy [36, 45, 50, 54–
56, 69, 75, 76].
Five studies [16, 51, 59, 61, 66] showed that swallowing
was least affected at baseline, worst immediately following
posttreatment (0–3months after treatment), and improved by
6–12 months after treatment and later. However, swallowing
usually did not return to pretreatment functioning level.
In four studies [49, 53, 58, 74], a relation between dose-
volume, dysphagia, and aspiration was found. Caudell et
al. [49] showed that a mean radiation dosage >41Gy with
>24% volume of the larynx being radiated was associ-
ated with increased percutaneous endoscopic gastrostomy
(PEG) dependency and aspiration. Akst et al. [46] correlated
advanced tumor stage and age >60 years with a deterioration
of swallowing.
Ackerstaff et al. [22] demonstrated improved oral intake
postradiotherapy and/or chemotherapy. Stenson et al. [70]
stated that weight remained unchanged after treatment (via
oral route), whereas Nourissat et al. [62] described a mean
weight loss of 2.2 kg posttreatment.
3.3. QoL. Twenty-five studies [22, 24, 25, 27–29, 31, 32,
35, 36, 42, 44, 47, 51, 53, 55, 59, 62, 64, 68, 72, 76–79]
described the short- and long-term effects of treatment for
HNC on patients’ general QoL. The European Organiza-
tion for Research and Treatment of Cancer (EORTC) C30-
questionnaire was used in fifteen studies [22, 24, 25, 27, 31,
32, 35, 42, 47, 55, 62, 64, 77–79] and the more HNC specific
EORTCH&N35was used in thirteen studies [22, 24, 25, 31, 32,
35, 36, 42, 47, 64, 77–79]. Other questionnaires that were used
included the University of Washington QoL Questionnaire
(UWQoL) [53, 68, 72, 76], theHead andNeckQoLorHNQoL
[53, 72], and the Xerostomia related QoL or XQoL [68, 72].
Follow-up time for QoL was up to six years after treatment
[35], including patients with tumors that were early staged
and patients with advanced tumors.
Although three studies [28, 72, 77] demonstrated
improvements in QoL, four studies [22, 36, 42, 54] reported
a decrease in general QoL as a result of radiotherapy and/or
BioMed Research International 7
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chemotherapy. Bansal et al. [27] found a significant decline
in physical, social, and emotional functioning as well as
in global health scores following a course of radiotherapy.
However, the patients’ functional scores improved one
month after treatment but did not reach pretreatment levels.
The health-related QoL (HRQoL) scores of the majority
of patients in the Bottomley et al. [78] study returned to
baseline at 48-month follow-up. These findings support the
findings of Ackerstaff et al. [22], Cohen et al. [51], Karlsson et
al. [32], List et al. [59], and Wilson et al. [76], who suggested
that HRQoL deteriorates significantly immediately after
treatment, with variable degrees of improvement 3–72
months after treatment.
3.4. Reported (Efficacy of) Speech Pathology Interventions.
We assessed the speech pathology interventions against the
following criteria: (a) whether a detailed description of the
intervention was provided; (b) whether the authors provided
a description of treatment duration and intensity; and (c)
what the speech pathology intervention outcomes were. The
reported efficacy of 14 speech pathology intervention studies
aimed at addressing problems in dysphagia, speech, voice,
and trismus is summarised in Table 4.
Of the 60 articles included in this review, 14 studies
[16, 23, 29, 31, 35, 40, 44, 46, 48, 56, 57, 69, 73, 74]
reported whether there was any treatment for the sequelae
of radiotherapy and/or chemotherapy. Of these intervention
studies, five focused on voice-related problems [23, 31, 35,
40, 44], two focused on trismus [48, 52], seven focused on
swallowing disorders [16, 35, 46, 56, 57, 69, 73], and one
study reported on both swallowing disorders and trismus
[74].
The three studies that investigated the treatment of
trismus [48, 52, 74] presented the most detailed information
on what the interventions involved. The study by Dijkstra et
al. [52] described a wide variety of trismus-specific therapies,
suggesting that most patients received a combination of
therapies. The patients in the van der Molen et al. [44] and
Kraaijenga et al. [35] studies did not receive any speech
therapy. The remainder of the studies reported that patients
received speech therapy; however, most of these studies did
not provide specific data on treatment duration or intensity.
None of the voice-related studies provided information on the
specific exercises prescribed to patients except Karlsson et al.
[31].
Of the eight studies on swallowing disorders, only Kotz et
al. [57] and van derMolen et al. [73] described the prescribed
exercises in detail. The aim of the latter study was to compare
the effectiveness of experimental rehabilitation to standard
rehabilitation in 49 advancedHNCpatients.The authors con-
cluded that preventive rehabilitation is feasible and effective
in reducing the extent and/or severity of various functional
short-term effects of chemoradiotherapy [74]. This finding
is supported by the 6-year follow-up study by Kraaijenga et
al. [35]. Kotz et al. [57] described a temporary improvement.
These are the only studies that provided detailed information
about the speech pathology intervention and reported on the
effectiveness of the intervention.
4. Discussion
In total, 60 studies met the inclusion criteria. The studies
described the effects of radiotherapy and/or chemotherapy on
the functions of the upper aerodigestive tract in patients with
HNC. The articles yielded by this systematic review vary in
their findings regarding tumor characteristics and treatment
modalities. As a result of this variability, no statistical pooling
was possible.We also set out to investigate the involvement of
speech pathologists in treating patients with HNC.
When considering treatment outcomes, voice quality
worsened at the start of radiotherapy and/or chemotherapy
but eventually improved after therapy finished. Dysphagia
can be a major side effect of HNC and its treatment. The
high incidence of dysphagia in this study population can
cause serious secondary consequences, such as malnutrition,
dehydration, an increased risk of aspiration, and, at worst,
death [80]. As dysphagia is a common sequela to oncological
treatment, early detection and treatment are needed to avoid
or minimise serious secondary complications [81].
The general description of the study population in Table 3
shows that there was great variability in both the location of
the tumor and the grading/staging, making comparisons of
these studies difficult. As the follow-up times varied in each
study, the outcomesmay be noncomparable.Thus, this review
shows that there is a need for more standardised approaches
to research in this field.
Additionally, a large range of outcome measures were
used, some of which are not validated.This calls into question
the reliability of results reported in some of the studies.
The use of validated and standardised assessments in future
research would provide more robust findings.
When considering the functional outcomes of radiother-
apy and/or chemotherapy, one of the most important factors
is whether the patient had received voice or swallowing
therapy. Interestingly, only 14 of the 60 included studies
reported whether the patients received any speech therapy.
Thus, in 46 articles functional results, such as voice quality,
are presented with no specification of whether the patient
received therapy. As some of these studies have a follow-up
of >2 years, it is fair to assume that patients sought help for
voice or swallowing problems. Therefore, the involvement of
speech therapy may be underreported, suggesting that the
presented outcomes in these studies are biased and raise
questions about their reliability.
When information was provided about treatment, only
six articles [31, 48, 52, 57, 73, 74] described in detail the
treatment intensity as the actual treatment. Furthermore,
these studies are the only five that include conclusions about
the efficacy of speech therapy in this specific population.
In the context of EBP, this finding demonstrates the need
for more research into the efficacy of speech pathology
interventions for patients with HNC receiving radiotherapy
and/or chemotherapy.
To enable the objective reporting of the effectiveness
of radiation and/or chemotherapy, baseline measurements
of different aspects of voice quality and swallowing are
required. To manage expectations, healthcare professionals
and patients need to bemade aware that some aspects of both
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Table 4: Overview of speech pathology interventions aimed at addressing problems in dysphagia, speech, voice, and trismus (𝑛 = 14).
Reference Topic
General description of
intervention and treatment
intensity/duration
Description of specific
exercises Conclusions specific to therapy
Agarwal et al.
2009 [23] Voice
All patients received counseling
and voice therapy by a trained
speech pathologist
No specific data provided on
treatment frequency/intensity
No description of exercises
provided
Forty-seven of 50 patients
showed compliance to the
therapy. No specific conclusions
of influence of provided therapy
on primary outcomes described
Akst et al.
2004 [46] Swallowing
Swallowing evaluation and
intervention when clinically
indicated
No description of exercises
provided
No specific conclusions of
influence of provided therapy on
primary outcomes described
Buchbinder et al.
1993 [48] Trismus
Six to 10 exercise sessions per day
for a 10-week period
Group 1: unassisted
exercises: reach maximum
MIO and closing, jaw
motion to left, right, and
protrusively
Group 2: unassisted
exercises: reach maximum
MIO and closing, jaw
motion to left, right, and
protrusively. Stacked
tongue depressors, to
mechanically increase MIO
(5 × 30 seconds per session)
Group 3: unassisted
exercises: reach maximum
MIO and closing, jaw
motion to left, right, and
protrusively. Combined
with theTheraBite System
(5 × 30 seconds per session)
The first four weeks no
differences between groups were
found. After week 4 minimal
improvements in groups 1 and 2
were found and group 3 still
improved. The highest increment
in MIO was reached in group 3
Dijkstra et al.
2007 [52] Trismus
Physical therapy for trismus,
median of 4 sessions
Physical therapy consisting
of
(i) Active range of motion
(ii) Hold and relax
(iii) Manual stretching
(iv) Joint distraction
Following therapeutic tools
are used in described
cohort:
(i) Rubber plugs
(ii) Tong blades
(iii) Dynamic bite opener
(iv) TheraBite System
MIO increases significantly after
physical therapy. History of HNC
decreases the effect of physical
therapy, compared to other
trismus patients
Frowen et al.
2010 [16] Swallowing
All patients were seen by a
speech pathologist as an aspect of
regular care
No description of exercises
provided
No specific conclusions of
influence of provided therapy on
primary outcomes described
Hutcheson et al.
2014 [56] Swallowing
All patients received prophylactic
swallowing therapy to avoid
nothing by mouth periods
during treatment
No specific data provided on
treatment frequency/intensity
Targeted swallowing
exercises
No specific conclusions of
influence of provided therapy on
primary outcomes described
Karlsson et al.
2015 [31] Voice
Group 1: voice therapy group
received 10 × 30-minute sessions
over 10 weeks
Group 2: vocal hygiene group: 1
session for vocal hygiene advice
Group 1: voice therapy
consisting of relaxation,
respiration, posture, and
phonation exercises
Group 2: vocal hygiene
advice
Patients treated with voice
therapy experienced greater
improvements compared to
patients that only received vocal
hygiene advice. Group 1 showed
a significant better functional
communication and HRQoL
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Table 4: Continued.
Reference Topic
General description of
intervention and treatment
intensity/duration
Description of specific
exercises Conclusions specific to therapy
Kotz et al.
2012 [57] Swallowing
Group 1: weekly treatment by
speech pathologist and daily 3 ×
10 home sessions of exercises.
Group 2: swallowing assessment
and treatment if necessary after
treatment
Group 1: prophylactic
swallowing therapy
consisting of effortful
swallow, tongue base
retraction exercises, super
supraglottic swallow, and
the Mendelssohn maneuver
Group 2: control group
only receive symptomatic
dysphagia treatment
Prophylactic swallowing therapy
improves swallowing at 3 and 6
months; later there were no
group differences found
Kraaijenga et al.
2014 [35]
Swallowing and
voice
Daily practice from the start of
the treatment until 1 year after
treatment
Two combined groups:
TheraBite System and
standard logopedic
swallowing exercises (the
same cohort as van der
Molen et al. 2011 [73])
Minimal voice and swallowing
difficulties were found 60 months
after treatment in patients treated
with prophylactic swallowing
exercises
Sanguineti et al.
2014 [40] Voice
75.8% of the patients received
speech therapy. No therapy was
provided to 30 patients
No specific data provided on
treatment frequency/intensity
No description of exercises
provided
No specific conclusions of
influence of provided therapy on
primary outcomes described
Starmer et al.
2014 [69] Swallowing
Patients received prophylactic
swallowing and trismus exercises
No description of exercises
provided
No specific conclusions of
influence of provided therapy on
primary outcomes described
van der Molen et al.
2011 [73] Swallowing
Patients received instructions in
advance of their oncological
treatment. Three times daily
exercises
Group 1: range-of-motion
exercises and three
strengthening exercises,
that is, the effortful swallow,
the Masako maneuver, and
the super supraglottic
swallow. Stretch holding for
10–30 seconds at a point of
mild discomfort
Group 2: stretch of the
mouth using the TheraBite
System and a strengthening
exercise: swallowing with
the tongue elevated to the
palate while maintaining
mouth opening at 50% of
its maximum. Stretch
holding for 10–30 seconds
at a point of mild
discomfort
Similar outcomes in both groups
were found. Preventive
rehabilitation can improve early
posttreatment functional
outcomes
van der Molen et al.
2012 [44] Voice
No specific speech or voice
therapy N/A N/A
van der Molen et al.
2013 [74]
Swallowing and
trismus
Study was aimed at describing
dose-effect relationships in two
treatment groups described in
earlier study. References to other
published study where treatment
regime is described
Group 1: standard exercises
Group 2: experimental
exercises
Any possible difference between
the two included treatment
groups is not described, nor
possible influence of the
respective treatments
HNC: head and neck cancer; HRQoL: health-related quality of life; MIO: maximum incisal opening; ROM: range of motion.
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voice and swallowing commonly do not recover to the level
prior to the oncological intervention [16]. Regarding effec-
tiveness of voice treatments, the following multidimensional
assessment is recommended [82]: a videolaryngostroboscopy
recording of the laryngeal structures and the vocal fold
vibration; an acoustic and a perceptual analysis of voice; a
voice-related questionnaire on QoL (e.g., the Voice Handicap
Index) [83]; and a functional health status questionnaire.
Such a protocol would be in line with the recommendations
for functional assessment of voice pathology as described by
the Committee on Phoniatrics of the European Laryngologi-
cal Society [84].
When describing aspects of swallowing function, both
fiber optic endoscopic evaluation of swallowing and videoflu-
oroscopy are considered to be the gold standard in dysphagia
assessment [85]. In addition to these tools, questionnaires
on HRQoL and functional health status are recommended
and should be integrated in the overall swallowing assess-
ment protocol. Repeatedmeasurements of outcomemeasures
should be performed in order to monitor any side effects of
the oncological intervention, to detect spontaneous recovery,
and to measure the effects of the speech pathology inter-
ventions. Apart from baseline measurements, posttreatment
and follow-up measurements should be used to monitor
functional and QoL outcomes.
Additional research is needed to develop clinical practice
guidelines to support evidence-based practice in the area of
dysphagia, speech, voice, and trismus following radiotherapy
and/or chemotherapy in patients with head and neck carci-
noma. These practice guidelines should bring together the
best available current evidence within a specific clinical area,
formulating evidence-based recommendations for clinicians
and present choices between different interventions that have
an impact on health and use of resources [86]. This system-
atic review summarised the effects of radiotherapy and/or
chemotherapy on the function of the upper aerodigestive
tract in patients with head and neck cancer. However, because
of the marked variation in treatment protocols and patient
characteristics, outcome data from the included studies
cannot be easily generalised. Recommendations for future
studies advocate the use of a multidimensional assessment
protocol, using well-validated measures and standardised
pretreatment, posttreatment, and follow-up measurements,
thus allowing for future meta-analysis of homogeneous out-
comes.
5. Conclusion
The studies included in this systematic review described a
wide variety of outcomes in patients with HNC following
radiotherapy and/or chemotherapy. The findings about the
long-term functional implications of radiotherapy and/or
chemotherapy in patients with HNC are inconclusive as a
result of the wide range of outcome measures used and the
possible influence of underreported speech therapy.
Future researchers need to consider targeting more
homogeneous groups using standardised treatment protocols
to improve the treatment outcomes, thereby decreasing the
side effects of the oncological treatments. Findings of these
studies need to inform the decision-making process in the
treatment of HNC so complications can be better predicted
with due consideration of the possible negative side effects to
the upper aerodigestive tract. Although the main objective of
most studies was to determine curing rates, the importance
of the functional implications of the side effects of oncol-
ogy treatments should not be overlooked, particularly their
impact on QoL. Finally, more research is needed to gain a
full understanding of the complexity and variety in the effects
of radiotherapy and/or chemotherapy on the functions of the
upper aerodigestive tract following HNC.
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